Identifying factors to predict benefit from bevacizumab in progressive glioblastoma multiforme (GBM).

被引：0
|
作者：
Gleeson, Jack Patrick
Alhusaini, Abdullah
O'Halloran, Philip
Harrold, Emily
Keegan, Niamh M.
Karadawi, Nabeeha Eltag
Mammadov, Emin
Kamel, Dalia
Egan, Keith
Molloy, Susan
Hennessy, Bryan T.
Breathnach, Oscar S.
Grogan, William
Morris, Patrick G.
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.e13515
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e13515
引用
收藏
页数：6
相关论文
共 50 条
  • [41] EFFICACY, SAFETY AND PATTERN OF RELAPSE OF BEVACIZUMAB (BEV) VERSUS CHEMOTHERAPY FOR RECURRENT GLIOBLASTOMA MULTIFORME (GBM): A MCGILL UNIVERSITY STUDY
    Sahebjam, S.
    Ang, C.
    Guiot, M.
    Garoufalis, E.
    Muanza, T.
    Del Maestro, R.
    Kavan, P.
    ANNALS OF ONCOLOGY, 2010, 21 : 330 - 330
  • [42] Phase II study of border zone stereotactic radiosurgery with bevacizumab in patients with recurrent or progressive glioblastoma multiforme
    Megan Mantica
    Jan Drappatz
    Frank Lieberman
    Constantinos G. Hadjipanayis
    L. Dade Lunsford
    Ajay Niranjan
    Journal of Neuro-Oncology, 2023, 164 : 179 - 190
  • [43] CORRELATION BETWEEN MRI SEQUENCES IS VARIABLE IN PATIENTS WITH PROGRESSIVE GLIOBLASTOMA MULTIFORME TREATED WITH BEVACIZUMAB PLUS CHEMOTHERAPY
    Thompson, Eric M.
    Dosa, Edit
    Neuwelt, Edward A.
    NEURO-ONCOLOGY, 2009, 11 (05) : 675 - 675
  • [44] Phase II study of border zone stereotactic radiosurgery with bevacizumab in patients with recurrent or progressive glioblastoma multiforme
    Mantica, Megan
    Drappatz, Jan
    Lieberman, Frank
    Hadjipanayis, Constantinos G. G.
    Lunsford, L. Dade
    Niranjan, Ajay
    JOURNAL OF NEURO-ONCOLOGY, 2023, 164 (1) : 179 - 190
  • [45] CLINICAL PREDICTIVE FACTORS OF INCREASE OVERALL SURVIVAL WITH BEVACIZUMAB/IRINOTECAN FOR PRIMARY RECURRENT GLIOBLASTOMA (GBM)
    Frenel, J. S.
    Leux, C.
    Tollec, S.
    Martin, S.
    Labbe, C.
    Loussouarn, D.
    Campone, M.
    ANNALS OF ONCOLOGY, 2010, 21 : 330 - 330
  • [46] SINGLE CENTRE EXPERIENCE OF BENEFIT OF CHEMOTHERAPY WITH 40GY/15# RADIOTHERAPY IN PATIENTS WITH GLIOBLASTOMA MULTIFORME (GBM)
    Streatfield, K.
    Davies, A.
    Glendenning, J.
    Forner, S. L.
    NEURO-ONCOLOGY, 2024, 26 : V107 - V107
  • [47] Can MRI-derived Factors Predict Survival in Patients with Glioblastoma Multiforme?
    Murakami, R.
    Nakamura, H.
    Hirai, T.
    Kitajima, M.
    Nakaguchi, Y.
    Nishimura, S.
    Uetani, H.
    Kuratsu, J.
    Yamashita, Y.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (02): : S275 - S276
  • [48] A phase II study of XL184 in patients (pts) with progressive glioblastoma multiforme (GBM) in first or second relapse
    De Groot, J. F.
    Prados, M.
    Urquhart, T.
    Robertson, S.
    Yaron, Y.
    Sorensen, A. G.
    Norton, A.
    Batchelor, T.
    Drappatz, J.
    Wen, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [49] Phase II study of border zone stereotactic radiosurgery with bevacizumab in patients with recurrent or progressive glioblastoma multiforme.
    Mantica, Megan
    Drappatz, Jan
    Lunsford, L. Dade
    Lieberman, Frank S.
    Niranjan, Ajay
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [50] Role of adjuvant or salvage radiosurgery in the management of unresected residual or progressive glioblastoma multiforme in the pre-bevacizumab era
    Niranjan, Ajay
    Kano, Hideyuki
    Iyer, Aditya
    Kondziolka, Douglas
    Flickinger, John C.
    Lunsford, L. Dade
    JOURNAL OF NEUROSURGERY, 2015, 122 (04) : 757 - 765
12345